| Literature DB >> 35216346 |
Beatriz Lozano-Ruiz1, Amalia Tzoumpa1, Claudia Martínez-Cardona1, David Moreno1, Ana M Aransay2,3, Ana R Cortazar3, Joanna Picó1, Gloria Peiró1,4, Juanjo Lozano2, Pedro Zapater1,2,5,6, Rubén Francés1,2,6,7, José M González-Navajas1,2,5,6.
Abstract
Absent in melanoma 2 (AIM2) is a cytosolic dsDNA sensor that has been broadly studied for its role in inflammasome assembly. However, little is known about the function of AIM2 in adaptive immune cells. The purpose of this study was to investigate whether AIM2 has a cell-intrinsic role in CD4+ T cell differentiation or function. We found that AIM2 is expressed in both human and mouse CD4+ T cells and that its expression is affected by T cell receptor (TCR) activation. Naïve CD4+ T cells from AIM2-deficient (Aim2-/-) mice showed higher ability to maintain forkhead box P3 (FOXP3) expression in vitro, while their capacity to differentiate into T helper (Th)1, Th2 or Th17 cells remained unaltered. Transcriptional profiling by RNA sequencing showed that AIM2 might affect regulatory T cell (Treg) stability not by controlling the expression of Treg signature genes, but through the regulation of the cell's metabolism. In addition, in a T cell transfer model of colitis, Aim2-/--naïve T cells induced less severe body weight loss and displayed a higher ability to differentiate into FOXP3+ cells in vivo. In conclusion, we show that AIM2 function is not confined to innate immune cells but is also important in CD4+ T cells. Our data identify AIM2 as a regulator of FOXP3+ Treg cell differentiation and as a potential intervention target for restoring T cell homeostasis.Entities:
Keywords: AIM2; CD4+; FOXP3; T cell; Treg; absent in melanoma 2; inflammasome; regulatory T cell
Mesh:
Substances:
Year: 2022 PMID: 35216346 PMCID: PMC8876789 DOI: 10.3390/ijms23042230
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1AIM2 expression is controlled by the TCR. (a) Total RNA samples from two different subjects (S1 and S2) were subjected to qRT-PCR for the amplification of Aim2 mRNA and visualized on an agarose gel after 30 cycles. NTCs were run on the same gel but were not contiguous. (b) Flow cytometry analysis of AIM2 expression in CD3+CD4+ T cells from peripheral blood mononuclear cells (PBMCs) of three different subjects (S1–S3). (c) Western blot analysis of AIM2 expression in CD4+ cells purified from PBMCs of two different subjects (S1–S2). (d) Total RNA samples from four different mouse CD4+ T cell samples (S1–S4) were subjected to qRT-PCR for the amplification of Aim2 mRNA and visualized on an agarose gel after 30 cycles. (e) Western blot analysis of AIM2 expression in mouse spleen CD4+ T cells. CD4+ T cells were stimulated with anti-CD3 and anti-CD28 (αCD3/28) antibodies with or without LPS pre-stimulation (2 h) and total protein extracts were collected at the indicated timepoints. Anti-mouse AIM2 and anti-mouse β-actin primary antibodies were used after immunoblot for detection of AIM2 expression and loading control, respectively. (f) Quantification of blot images performed using ImageJ software (au; arbitrary units). Data were analyzed using Sidak’s multiple comparison test and are displayed as scatter plot with median ± range; * p < 0.05. Data are representative of three different experiments with similar results. NTC = non-template control.
Figure 2Lack of AIM2 promotes FOXP3 expression in vitro but does not affect the suppressive ability of Treg cells. (a) Cytokine levels in culture supernatants of splenic CD4+ T cells from WT or Aim2 mice stimulated with anti-CD3/CD28 antibodies for 24 h. (b) RT-qPCR analysis of Foxp3, Tbx21, Gata3 and Rorc mRNA expression in splenic CD4+ T cells isolated from WT or Aim2 mice (n = 4/group) and stimulated with anti-CD3/CD28 (αCD3/28) antibodies for the indicated timepoints. (c) Flow cytometry analysis of FOXP3 expression in naïve CD4+ T cells from WT or Aim2 mice cultured under Treg polarizing conditions for 3 or 5 days. Data are representative of two experiments with a total of n = 6/group. (d) Quantification of FOXP3+ cells from the flow cytometry analysis shown in (c). (e) Flow cytometry of the proliferation of naïve T cells (Tn) in the absence of Treg cells (No Treg) or in the presence of Treg cells at different ratios. (f) Quantification of proliferating T cells from the flow cytometry analysis shown in (e). Note: * p < 0.05, ** p < 0.01, *** p < 0.001. The data were analyzed using the Mann-Whitney U test (a,d) or two-way ANOVA with Sidak’s multiple comparison test (b,f) and are displayed as mean ± standard deviation (b) or as median ± interquartile range (a,d,f).
Figure 3RNAseq analysis in naïve T cells and during Treg polarization conditions. (a–c) Gene set enrichment analysis (GSEA) of CD4+ naïve T cells (Tn) from WT and Aim2 and from WT and Aim2 T cells stimulated under Treg polarizing conditions (Treg) for 2 days (n = 4/group). GO = gene ontology database; CC = cellular component; BP = biological process; NES = normalized enrichment score; RA = reactome database. (d) Heatmap showing the expression of Treg-associated genes in Tn and Treg from WT and Aim2 mice (n = 4/group). Color coded values represent log2 values of the normalized counts, mean-centered for each gene. (e) GSEA analysis of Treg-associated genes in Tn (left) and Treg (right) cells from WT and Aim2 mice (n = 4/group).
Figure 4Aim2 naïve T cells induce less body weight loss in the adoptive transfer model. Rag1 recipient mice were transferred with FACS-sorted naïve CD4+ T cells (CD4+CD45RBhighCD25−) from WT (n = 14) or Aim2 (n = 14) mice. Cotransfer groups received WT naïve T cells plus CD4+CD45RBlowCD25+ regulatory T (Treg) cells from either WT (n = 8) or Aim2 (n = 10) mice. Mice were then monitored for colitis induction and sacrificed 15 weeks after transfer. (a,b) Percentages of initial body weight (BW) in the cotransfer groups (a) or in the Rag1 mice transferred only with naïve T cells from WT or Aim2 donors (b). (c) Measurement of colon length in mice transferred with naïve T cells from WT or Aim2 donors. (d) Quantification of the histopathologic score of colitis in each group of mice. (e) Hematoxylin and eosin staining of colons from each group of recipient mice (original magnification, ×10). Scale bars represent 200 μm. (a,b) Data are from one experiment representative of two independent experiments. (c,d) Pooled data from two independent experiments. Note: * p < 0.05, ** p < 0.01. Data were analyzed using a two-way ANOVA with Holm–Sidak multiple comparison test and are displayed as mean ± standard deviation (a,b), or using a Mann-Whitney U test and displayed as median ± interquartile range (c,d).
Figure 5Aim2 naïve T cells show increased differentiation into FOXP3+ cells in vivo. (a) Flow cytometry analysis of FOXP3 expression in splenic CD4+ cells isolated from Rag1 mice 15 weeks after transfer of naïve T cells (CD4+CD45RBhighCD25−) from WT (n = 14) or Aim2 (n = 14) mice, or co-transferred with WT naïve T cells plus CD4+CD45RBlowCD25+ regulatory T (Treg) cells from either WT (n = 8) or Aim2 (n = 10) mice. Images are representative of two independent experiments. (b) Quantitative analysis of the percentages of FOXP3+ cells in the spleens of Rag1 mice after transfer of naïve T cells from WT or Aim2 mice. (c,d) Cytokine levels in culture supernatants of CD4+ T cells isolated from the spleens of Rag1 mice after transfer of WT or Aim2 naïve T cells as described in (a). Cells were stimulated with anti-CD3/CD28 antibodies for 24 h. (e) Immunohistochemistry analysis of FOXP3+ cells in colonic tissue of Rag1 mice receiving either WT or Aim2 naïve T cells as described in (a). Scale bars represent 100 μm (top photographs, original magnification ×20) or 50 μm (bottom photographs, original magnification ×40). Data shown are representative of one experiment with 7 mice per group. (f) Quantitative analysis of the immunohistochemistry analysis described in (e). Note: ** p < 0.01, *** p < 0.001, ns = not significant. Data were analyzed using a Mann-Whitney U test and displayed as median ± interquartile range (b–d,f).